Key clinical point: PRN1008 improved disease activity and induced remission in pemphigus.
Major finding: At the end of the 24-week study, 70% experienced a clinical response and 25% experienced remission.
Study details: The open-label study comprised 27 patients.
Disclosures: Principia Biopharma is developing the molecule and sponsored the study. Dr. Murrell designed the study and reported a financial relationship with Principia, as well as with numerous other pharmaceutical companies.
Murrell D et al. AAD 2019, Session S034.